This year's Futures National Conference, hosted by CureDuchenne for the Duchenne and Becker MD communities, is scheduled to ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

It is designed to address the root cause of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy. A Scotiabank analyst recently initiated coverage on Edgewise with ...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Newborn screening is also cost-effective. Testing that takes just a few dollars per baby can save families and the health ...

One of the most common forms of muscular dystrophy is Duchenne Muscular Dystrophy. Globally, Duchenne is the most prevalent form of muscular dystrophy in children. It primarily affects boys, and it is ...

Columnist Patrick Moeschen highlights some key federal programs and pieces of legislation in the history of muscular ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...